Kensei Yamaguchi
- Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
2020/03/09 by Akihito Kawazoe, Kensei Yamaguchi, Hisateru Yasui +19 · 1 citation
Medicine · #Cancer Immunotherapy and Biomarkers #Esophageal Cancer Research and Treatment #Gastric Cancer Management and Outcomes